Can β-catenin, Tenascin and Fascin be potential biomarkers for personalized therapy in Gastric carcinoma?

• Published in: Journal of immunoassay & immunochemistry Vol. 44; no. 5-6; pp. 396 - 417
• Main Authors: Elkady, Noha, Aldesoky, Amira I, Allam, Dina Mohamed
• Format: Journal Article
• Language: English
• Published: New York Taylor & Francis 02.11.2023; Marcel Dekker, Inc
• Subjects: Abnormalities; Biomarkers; Cancer; Carcinoma; Chemoresistance; Chemotherapy; Fascin; Gastric cancer; Gastric carcinoma; Immunohistochemistry; Lymph nodes; Metastases; Nodules; Parameters; predictive; prognostic; response to therapy; Survival; Tenascin; Therapeutic applications; Therapeutic targets; β-Catenin
• ISSN: 1532-1819; 1532-4230
• DOI: 10.1080/15321819.2023.2251564

Gastric carcinoma (GC) is one of the most prevalent cancers worldwide and the fourth leading cause of cancer-related death. Studying the molecular profile of GC is essential for developing targeted therapies. β-catenin, Tenascin, and Fascin expression are among the molecular abnormalities that are claimed to cause GC progression and chemoresistance. Therefore, they could be used as potential therapeutic targets. This study aimed to evaluate β-catenin, Tenascin, and Fascin expression and their possible roles as prognostic and predictive biomarkers in GC using immunohistochemistry. This retrospective study included 84 GC cases. Tissue microarrays were constructed, followed by β-catenin, Tenascin, and Fascin immunostaining. Their expression was assessed and compared with clinicopathological parameters and survival data. The study results revealed that β-catenin nucleocytoplasmic expression, positive Tenascin, and Fascin expressions were detected in 86.9%, 70%, and 59.5% of cases, respectively. Their expression was significantly associated with poor prognostic parameters, such as deeper tumor invasion, lymph node metastasis, advanced pathological stage, vascular invasion, positive omental nodules, poor response to chemotherapy, and short overall survival. Hence, nucleocytoplasmic β-catenin expression together with Tenascin and Fascin positivity can be potential prognostic and predictive markers, and they can be used as therapeutic targets for GC.